Image Place holder

Sepideh Mokhtari, MD


Specialty: Neurology
Program: Neuro-Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Cancer Types Treated: Brain Cancer, Glioblastoma, Hodgkin Lymphoma, Melanoma, Meningioma, Neurofibromatosis, Non-Hodgkin Lymphoma

Dr. Sepideh Mokhtari is an Associate Member in the Department of Neuro-Oncology at Moffitt Cancer Center. Dr. Mokhtari received her MD from Texas A&M College of Medicine in Temple, TX. She completed a Neurology Residency at Houston Methodist Hospital, where she also served as Chief Resident. She most recently completed a Neuro-Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Mokhtari’s clinical interests are primarily in brain tumors and neurologic complications of cancer. Her research focus is the quality of care for cancer patients with neurologic complications and primary brain tumors. In addition, her research interests include patients with meningioma and glioblastoma with or without other neurologic illness.

Education & Training

Board Certification:

  • Neuro-Oncology

Fellowship:

  • Memorial Sloan Kettering Cancer Center - Neuro-Oncology

Residency:

  • Houston Methodist Hospital - Neurology

Medical School:

  • Texas A&M - MD
Participating Trials

CLINICAL TRIAL 19433
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases
Condition:
Intervention: Avastin (Bevacizumab); Bevacizumab; Dexamethasone; Placebo; prednisone
Open

CLINICAL TRIAL 18574
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab; Temodal (Temozolomide); Temozolomide
Open

CLINICAL TRIAL 18647
A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab; Placebo; Temodal (Temozolomide); Temozolomide
Open

CLINICAL TRIAL 18880
A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 19385
A Randomized Phase 2 trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma who have not Received Prior VEGF Therapy
Condition:
Intervention: AZD2171 (Cediranib); Avastin (Bevacizumab); Bevacizumab; Cediranib (Recentin); FMISO; Olaparib (Lynparza)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Feb. Pubmedid: 29392582.
  • Sahebjam S, Stallworth DG, Mokhtari S, Tran ND, Arrington JA. Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors. Cancer Control. 2017 Apr;24(2):180-186. Pubmedid: 28441372.